SynthesisFrontiers in nutrition2025
Prognostic nutritional index and survival in prostate cancer: an updated systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the predictive value of the prognostic nutritional index (PNI) in prostate cancer patients. Compared with previous reviews, this study is the first to systematically grade and evaluate the quality of evidence regarding the association between PNI and prostate cancer prognosis using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework, which can provide more reliable and transparent evidence for clinical practice. Methods: A systematic search was conducted across PubMed, Embase, Web of Science, and Cochrane databases up to June 2025. Study quality was assessed using the Newcastle-Ottawa Scale. Outcomes included associations between PNI and overall survival (OS) and progression-free survival (PFS). Meta-analysis, Egger's test, and sensitivity analysis were performed using Review Manager 5.4.1 and Stata 15.1. The certainty of evidence for each outcome was evaluated and graded according to GRADE. Results: The systematic search identified 857 related studies, with 11 studies included in the meta-analysis. The meta-analysis revealed that a lower PNI was significantly associated with shorter OS (hazard ratio (HR): 2.03; 95% confidence interval (CI): 1.68, 2.46; Conclusions: Low PNI is associated with shorter OS and PFS in prostate cancer patients. Considering the inherent limitations of this study, more prospective studies are needed to confirm the association between PNI and the prognosis of prostate cancer patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251154118, identifier: CRD420251154118.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.